# A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

> **NCT06831344** · PHASE1 · COMPLETED · sponsor: **Phathom Pharmaceuticals, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Vonoprazan ODT-1 or ODT-2 without Water
- **DRUG:** Vonoprazan ODT-1 or ODT-2 with Water
- **DRUG:** Vonoprazan (Reference)

## Key facts

- **NCT ID:** NCT06831344
- **Lead sponsor:** Phathom Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-14
- **Primary completion:** 2025-04-05
- **Final completion:** 2025-04-10
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831344, "A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06831344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*